Lineage Therap Reports Promising OpRegen Study Results

An announcement from Lineage Therap ( (LCTX) ) is now available.

Lineage Cell Therapeutics announced the 36-month visual acuity results from a Phase 1/2a clinical study of RG6501 (OpRegen) in patients with geographic atrophy secondary to age-related macular degeneration. The results, presented at Clinical Trials at the Summit 2025, showed sustained improvement in visual acuity and retinal structure in patients who received extensive OpRegen cell therapy coverage, suggesting potential long-term benefits of the therapy. These findings could enhance Lineage’s position in the biotechnology industry by demonstrating the efficacy of their cell therapy in treating advanced ophthalmic conditions.

The most recent analyst rating on (LCTX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lineage Therap stock, see the LCTX Stock Forecast page.

Spark’s Take on LCTX Stock

According to Spark, TipRanks’ AI Analyst, LCTX is a Neutral.

Lineage Cell Therapeutics’ overall score is primarily driven by strong earnings call highlights, indicating progress in significant programs and financial stability. However, financial performance challenges and unattractive valuation metrics weigh down the score. Bullish technical indicators provide some positive outlook, though caution is advised due to overbought conditions.

To see Spark’s full report on LCTX stock, click here.

More about Lineage Therap

Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or ‘off the shelf’, cell therapies for serious neurological and ophthalmic conditions. The company’s programs are based on a proprietary cell-based technology platform, which involves the creation of specialized human cells to replace or support damaged cells in the body.

Average Trading Volume: 1,503,280

Technical Sentiment Signal: Hold

Current Market Cap: $216.9M

For detailed information about LCTX stock, go to TipRanks’ Stock Analysis page.